#METABOLOMICS WORKBENCH hormel101_20170810_150108_mwtab.txt DATATRACK_ID:1210 STUDY_ID:ST000859 ANALYSIS_ID:AN001384 PROJECT_ID:PR000575
VERSION             	1
CREATED_ON             	August 11, 2017, 12:34 pm
#PROJECT
PR:PROJECT_TITLE                 	Mayo Pilot and Feasiblity: Targeting Myelin Metabolism of Kallikrein 6 Signals
PR:PROJECT_TITLE                 	through PAR1 and PAR2 to Enchance Recovery of Function after SCI
PR:PROJECT_SUMMARY               	CNS trauma generates a proteolytic imbalance contributing to secondary injury,
PR:PROJECT_SUMMARY               	including axonopathy and neuron degeneration. Kallikrein 6 (Klk6) is a serine
PR:PROJECT_SUMMARY               	protease implicated in neurodegeneration and here we investigate the role of
PR:PROJECT_SUMMARY               	protease activated receptors 1 (PAR1) and PAR2 in mediating these effects in
PR:PROJECT_SUMMARY               	mice with spinal cord injury (SCI). This project conducts untargeted Profiling
PR:PROJECT_SUMMARY               	(unbiased metabolomics assay) and targeted lipid analysis. The lipid assays are
PR:PROJECT_SUMMARY               	1) free fatty acid composition of lipids; 2) free fatty acid panel; 3)
PR:PROJECT_SUMMARY               	cholesterol concentration (free and bound); 4) Ceramides, including galactosyl
PR:PROJECT_SUMMARY               	and glucosyl; 5) sphingomyelin.
PR:INSTITUTE                     	Mayo Clinic
PR:LAST_NAME                     	Scarisbrick
PR:FIRST_NAME                    	Isobel
PR:ADDRESS                       	200 First Street SW, Rochester, MN 55905
PR:EMAIL                         	scarisbrick.isobel@mayo.edu
PR:PHONE                         	507-284-0124
#STUDY
ST:STUDY_TITLE                   	Targeted Galactosyl Sphingolipid Concentration in Kallikrein 6 Mice after SCI
ST:STUDY_SUMMARY                 	Targeted Galactosyl Sphingolipids in Kallikrein 6 Mice after SCI. The samples
ST:STUDY_SUMMARY                 	submitted are purified myelin preparations from the postnatal day 21, 60, or 90
ST:STUDY_SUMMARY                 	mouse spinal cord (SC). There are 12 samples total in Project 3, n=3 for K6+/+
ST:STUDY_SUMMARY                 	or K6-/- at either P21 or P90.
ST:INSTITUTE                     	Mayo Clinic
ST:LAST_NAME                     	Scarisbrick
ST:FIRST_NAME                    	Isobel
ST:ADDRESS                       	200 First Street SW, Rochester, MN 55905
ST:EMAIL                         	scarisbrick.isobel@mayo.edu
ST:PHONE                         	507-284-0124
#SUBJECT
SU:SUBJECT_TYPE                  	Mouse
SU:SUBJECT_SPECIES               	Mus musculus
SU:TAXONOMY_ID                   	10090
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data
SUBJECT_SAMPLE_FACTORS           	-	ms6025-1	group:K6+/+	sex=Male; tissue=Tissue (SC); species=Mouse
SUBJECT_SAMPLE_FACTORS           	-	ms6025-2	group:K6+/+	sex=Male; tissue=Tissue (SC); species=Mouse
SUBJECT_SAMPLE_FACTORS           	-	ms6025-3	group:K6+/+	sex=Male; tissue=Tissue (SC); species=Mouse
SUBJECT_SAMPLE_FACTORS           	-	ms6025-4	group:K6+/+	sex=Male; tissue=Tissue (SC); species=Mouse
SUBJECT_SAMPLE_FACTORS           	-	ms6025-5	group:K6+/+	sex=Male; tissue=Tissue (SC); species=Mouse
SUBJECT_SAMPLE_FACTORS           	-	ms6025-6	group:K6+/+	sex=Male; tissue=Tissue (SC); species=Mouse
SUBJECT_SAMPLE_FACTORS           	-	ms6025-7	group:K6+/+	sex=Male; tissue=Tissue (SC); species=Mouse
SUBJECT_SAMPLE_FACTORS           	-	ms6025-8	group:K6+/+	sex=Male; tissue=Tissue (SC); species=Mouse
SUBJECT_SAMPLE_FACTORS           	-	ms6025-9	group:K6+/+	sex=Male; tissue=Tissue (SC); species=Mouse
SUBJECT_SAMPLE_FACTORS           	-	ms6025-10	group:K6+/+	sex=Male; tissue=Tissue (SC); species=Mouse
SUBJECT_SAMPLE_FACTORS           	-	ms6025-11	group:K6-/-	sex=Male; tissue=Tissue (SC); species=Mouse
SUBJECT_SAMPLE_FACTORS           	-	ms6025-12	group:K6-/-	sex=Male; tissue=Tissue (SC); species=Mouse
SUBJECT_SAMPLE_FACTORS           	-	ms6025-13	group:K6-/-	sex=Male; tissue=Tissue (SC); species=Mouse
SUBJECT_SAMPLE_FACTORS           	-	ms6025-14	group:K6-/-	sex=Male; tissue=Tissue (SC); species=Mouse
SUBJECT_SAMPLE_FACTORS           	-	ms6025-15	group:K6-/-	sex=Male; tissue=Tissue (SC); species=Mouse
SUBJECT_SAMPLE_FACTORS           	-	ms6025-16	group:K6-/-	sex=Male; tissue=Tissue (SC); species=Mouse
SUBJECT_SAMPLE_FACTORS           	-	ms6025-17	group:K6-/-	sex=Male; tissue=Tissue (SC); species=Mouse
SUBJECT_SAMPLE_FACTORS           	-	ms6025-18	group:K6-/-	sex=Male; tissue=Tissue (SC); species=Mouse
SUBJECT_SAMPLE_FACTORS           	-	ms6025-19	group:K6-/-	sex=Male; tissue=Tissue (SC); species=Mouse
SUBJECT_SAMPLE_FACTORS           	-	ms6025-20	group:K6-/-	sex=Male; tissue=Tissue (SC); species=Mouse
#COLLECTION
CO:COLLECTION_SUMMARY            	Tissue is from adult mouse spinal cord (SC). We are submitting these samples for
CO:COLLECTION_SUMMARY            	Untargeted Profiling (unbiased metabolomics assay) and for lipid analysis. The
CO:COLLECTION_SUMMARY            	lipid assays we request are 1) free fatty acid composition of lipids; 2) free
CO:COLLECTION_SUMMARY            	fatty acid panel; 3) cholesterol concentration (free and bound); 4) Ceramides,
CO:COLLECTION_SUMMARY            	including galactosyl and glucosyl; 5) sphingomyelin. The Untargeted profiling is
CO:COLLECTION_SUMMARY            	our top priority, followed by the lipid assays as listed. All samples were snap
CO:COLLECTION_SUMMARY            	frozen at the point of harvest and approximate weights are provided. The samples
CO:COLLECTION_SUMMARY            	are submitted as intact pieces of tissue. There are two different genotypes
CO:COLLECTION_SUMMARY            	(K6+/+ and K6-/-) and 20 samples total, n=5 for each group that includes
CO:COLLECTION_SUMMARY            	P21(K6+/+); P90 (K6+/+); P21 (K6-/-); and P90 (K6-/-). We would like to make
CO:COLLECTION_SUMMARY            	comparisons across the 4 groups.
#TREATMENT
TR:TREATMENT_SUMMARY             	A 3g Clip produces moderate SCI including demyelination and clinical impairment
TR:TREATMENT_SUMMARY             	and we recently published a detailed methodology. At 1 week after injury, the 3g
TR:TREATMENT_SUMMARY             	injured mice are expected to have an average Basso Mouse Scale score (BMS)=5 on
TR:TREATMENT_SUMMARY             	a 9 point scale such that they have frequent plantar stepping with no or some
TR:TREATMENT_SUMMARY             	coordination. This level of impairment was chosen to provide a sufficient window
TR:TREATMENT_SUMMARY             	to observe recovery.
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	"Myelin galactosyl sphinolipid concentrations from mouse spinal cord Lipids will
SP:SAMPLEPREP_SUMMARY            	be quantified in myelin isolated in high yield and purity by subcellular
SP:SAMPLEPREP_SUMMARY            	fractionation from the lumbosacral spinal cord. While there are no absolutely
SP:SAMPLEPREP_SUMMARY            	‘myelin-specific’ lipids, galactocerebroside is the most typical of myelin
SP:SAMPLEPREP_SUMMARY            	in the adult nervous system being directly proportional to the amount of myelin.
SP:SAMPLEPREP_SUMMARY            	Sulfatide is another galactolipid enriched in myelin. Together with cholesterol,
SP:SAMPLEPREP_SUMMARY            	these form 78% of the total amount of lipid in the myelin membrane and each will
SP:SAMPLEPREP_SUMMARY            	be quantified using LC/MS/MS. A highly sensitive assay for galactocerebroside
SP:SAMPLEPREP_SUMMARY            	was recently established by the Mayo Metabolomics Core and can be implemented
SP:SAMPLEPREP_SUMMARY            	immediately. The LC/MS/MS panel for free fatty acids, including the very long
SP:SAMPLEPREP_SUMMARY            	chain fatty acids found in myelin is also routinely performed by the Core.
SP:SAMPLEPREP_SUMMARY            	Cholesterol will be quantified using an NMR-based approach by the Mayo Dept. of
SP:SAMPLEPREP_SUMMARY            	Laboratory Medicine Clinical Core. Additionally, we have a plan in place with
SP:SAMPLEPREP_SUMMARY            	the Metabolomics Core to develop LC/MS/MS assays for sulfatide and sphingomyelin
SP:SAMPLEPREP_SUMMARY            	during the Pilot proposal. Having quantitative assays for each of these key
SP:SAMPLEPREP_SUMMARY            	myelin lipids will facilitate our goal to comprehensively profile myelin lipid
SP:SAMPLEPREP_SUMMARY            	metabolism and will form foundational assays for a future NIH grant focused on
SP:SAMPLEPREP_SUMMARY            	myelin metabolism."
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_TYPE           	HILIC
CH:INSTRUMENT_NAME               	Waters Acquity
CH:COLUMN_NAME                   	AMT HALO HILIC 2.7, 4.6x150mm
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
#MS
MS:INSTRUMENT_NAME               	Thermo Quantiva QQQ
MS:INSTRUMENT_TYPE               	Triple quadrupole
MS:MS_TYPE                       	ESI
MS:ION_MODE                      	POSITIVE
#MS_METABOLITE_DATA
MS_METABOLITE_DATA:UNITS         	ng/vial
MS_METABOLITE_DATA_START
Samples	ms6025-1	ms6025-2	ms6025-3	ms6025-4	ms6025-5	ms6025-6	ms6025-7	ms6025-8	ms6025-9	ms6025-10	ms6025-11	ms6025-12	ms6025-13	ms6025-14	ms6025-15	ms6025-16	ms6025-17	ms6025-18	ms6025-19	ms6025-20
Factors	group:K6+/+	group:K6+/+	group:K6+/+	group:K6+/+	group:K6+/+	group:K6+/+	group:K6+/+	group:K6+/+	group:K6+/+	group:K6+/+	group:K6-/-	group:K6-/-	group:K6-/-	group:K6-/-	group:K6-/-	group:K6-/-	group:K6-/-	group:K6-/-	group:K6-/-	group:K6-/-
Gal-Sph	0.29	not found	not found	not found	not found	1.85	1.76	2.04	2.60	2.14	not found	not found	not found	not found	not found	1.73	1.59	1.21	1.40	2.36
Gal-C16-Cer	19	13	21	20	25	31	30	33	38	38	29	27	24	28	13	33	30	31	39	37
Gal-C18-Cer	877	617	864	787	957	1547	1266	1424	1539	1672	1039	1026	1040	1031	596	1505	1313	1256	1654	1613
Gal-C24:1-Cer	3330	2492	3296	3274	3798	6103	6179	6748	6923	6969	3895	3788	3814	4741	2562	6448	6497	6367	6975	6832
MS_METABOLITE_DATA_END
#METABOLITES
METABOLITES_START
metabolite_name
Gal-Sph
Gal-C16-Cer
Gal-C18-Cer
Gal-C24:1-Cer
METABOLITES_END
#END